What ENTEROME does

Enterome is a clinical-stage biopharmaceutical company founded in 2012 in Paris, France, developing immunomodulatory therapeutics derived from the human gut microbiome. The company's core technology is the Mimicry drug discovery platform, which mines a proprietary database of more than 20 million full-length commensal bacterial proteins using proprietary biocomputational tools (including the GeneMark-HM gene prediction software co-developed with Gene Probe Inc.) to identify bacterial peptides that closely mimic human tumor-associated antigens, hormones, or cytokines. From this platform, Enterome has built three therapeutic franchises: OncoMimics for cancer (lead candidate EO2463 in indolent non-Hodgkin lymphoma with FDA Fast Track and Orphan Drug Designations; EO2401 in glioblastoma and adrenal tumors; EO4010 in metastatic colorectal cancer), EndoMimics for inflammatory and autoimmune diseases (lead candidate EB1010 partnered with Nestlé Health Science for food allergies and IBD), and AllerMimics, a new generation of MHC-II restricted allergen mimics for food allergies.

The company's business model is that of a venture-backed pre-commercial biopharma: it generates no product revenue today and funds operations through equity financing (~€155 million raised across 10+ rounds from 2011 to 2025, including a €46.3M round in June 2020 and a $19M round in June 2025), strategic grants (e.g., €3M from LLS TAP in October 2023), and partnership economics from co-development and licensing agreements (Nestlé Health Science for EndoMimics/EB1010; Takeda for sibofimloc). Future revenue is expected to come from pharmaceutical product sales, milestone payments, and royalties on net sales through partnerships for global commercialization. Enterome's customer base today consists of clinical trial investigator sites (Mayo Clinic, Fred Hutchinson, Dana-Farber, MD Anderson) and pharmaceutical/financial partners rather than commercial end-buyers. Leadership includes co-founder/CEO Pierre Belichard, Chairman Peter Hirth (co-founder of Plexxikon, sold to Daiichi Sankyo), CMO Jan Fagerberg (ex-Roche, ex-Amgen), and board members representing IFLI, Seventure Partners, Lundbeckfonden BioCapital, Primo Capital, and SymBiosis.

Name

ENTEROME

Legal name

Enterome SA

Website

https://enterome.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

51–100 employees

Short description

Enterome is a clinical-stage Paris-based biopharmaceutical company developing microbiome-derived peptide immunotherapies (OncoMimics, EndoMimics, AllerMimics) for cancer, inflammatory diseases, and food allergies, with lead candidate EO2463 in Phase 1/2 trials for indolent non-Hodgkin lymphoma.

Ownership category

akta.pro rank

Product category

Immuno-Oncology Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Immunology & Inflammation Pharmaceuticals (HLAIAAAD)

akta.pro secondary industries

Food Allergy Evaluation & Management (HLAKAAAD), Gastroenterology Specialty Pharmaceuticals (HLAIACAE), Therapeutic Peptides & Protein/Peptide Biologics (HLAAAAAH)

Keywords

• Cancer immunotherapy
• Microbiome therapeutics
• Peptide drug discovery
• Immuno-oncology treatments
• Clinical-stage biopharmaceutical

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Revenue: Pre-revenue clinical stage company. Future revenue expected from commercialization of OncoMimics™ pipeline candidates (EO2463, EO2401, EO4010) upon regulatory approval. Company has received €3M strategic investment from LLS TAP and $19M private financing to fund clinical development.
2. Partnership and Licensing Revenue: Co-development and licensing agreements with pharmaceutical partners such as Nestlé Health Science (for EndoMimics™ EB1010) and Takeda (for sibofimloc). May include upfront payments, milestone payments, and royalties on net sales.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Enterome is a clinical-stage biopharmaceutical company developing off-the-shelf, multi-targeted cancer immunotherapies derived from gut microbiome peptides. Its lead candidates include EO2463 for indolent non-Hodgkin lymphoma, EO2401 for glioblastoma and adrenal tumors, and EO4010 for metastatic colorectal cancer. The company also develops EndoMimics™ oral bioactives for inflammatory/autoimmune diseases (lead EB1010, partnered with Nestlé Health Science) and AllerMimics™ therapeutics for food allergies, all powered by its proprietary Mimicry drug discovery platform.

Product overview

ENTEROME is a clinical-stage biopharmaceutical company pioneering OncoMimics™, a new class of off-the-shelf, multi-targeted in vivo immune therapies. The company's core technology platform uses proprietary biocomputational tools and machine learning to mine a database of 20+ million gut microbiome proteins to identify bacterial peptides that closely mimic tumor-associated antigens. The OncoMimics™ approach activates pre-existing effector-memory CD8+ T cells to generate rapid, potent cytotoxic responses against cancer cells. ENTEROME's proprietary clinical programs include EO2463 (Phase 2 for indolent non-Hodgkin lymphoma), EO2401 (Phase 1/2 for glioblastoma and adrenal tumors), and EO4010 (Phase 1/2 for metastatic colorectal cancer). The company also maintains pipeline platforms in EndoMimics™ (for inflammatory diseases, including partnered EB1010 with Nestlé Health Science) and AllerMimics™ (for food allergies).

Differentiator

Problem solved

Functional benefit

Brands

• OncoMimics: A specific combination of bacterial peptides derived from gut microbiome that closely mimic tumor-associated antigens (TAAs) or lineage-specific markers in solid and liquid tumors, generating powerful immune responses against cancer cells.
• EndoMimics
• AllerMimics

Products and services

• EO2463 Off-the-shelf OncoMimics™ active immunotherapy combining four synthetic peptides (mimics of CD20, CD22, CD37, and CD268/BAFF-R B-cell lineage markers) plus CD4 helper peptide UCP2. Currently in Phase 2 SIDNEY trial for indolent non-Hodgkin lymphoma as monotherapy in watch-and-wait patients and in combination with rituximab/lenalidomide. Has received FDA Fast Track and Orphan Drug Designations for follicular lymphoma.
• EO2401 Off-the-shelf OncoMimics™ multi-targeted immunotherapy combining three peptides (EO2316, EO2317, EO2318) that mimic tumor-associated antigens IL13Ra2, BIRC5/survivin, and FOXM1, plus CD4 helper peptide UCP2. In Phase 1/2 ROSALIE trial for recurrent glioblastoma (completed enrollment of 100 patients) and SPENCER trial for adrenal tumors.
• EO4010 OncoMimics™ peptide-based immunotherapy combining five microbial-derived peptides targeting tumor-associated antigens BIRC5, FOXM1, UBE2C, CDC20, and KIF2C commonly observed in colorectal cancer patients. In Phase 1/2 AUDREY trial for metastatic colorectal cancer.
• EB1010 Lead EndoMimics™ compound being co-developed with Nestlé Health Science; a potent local inducer of IL-10 designed for improved therapeutic outcomes in food allergies and inflammatory bowel disease (IBD).

Quantifiable outcome

• 90% immune response rate (43/48 patients) with EO2463 in indolent NHL
• +6 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Three partnerships are on record, tiered minor and core.

• BIOASTER InstituteminorStrategic or Co-development Partner · 3 February 2020Research collaboration to provide new insights into immunological mechanisms underpinning Enterome's Oncomimicry platform. Leverages BIOASTER's expertise in microbiome sciences, microbiology engineering, immune-monitoring, and gnotobiology using proprietary GNOTOMICE model.
• Nestlé Health SciencecoreStrategic or Co-development PartnerCo-development partnership to successfully develop and commercialize Enterome's lead EndoMimics pipeline candidate EB1010, a potent local inducer of IL-10 targeting food allergies and inflammatory bowel disease (IBD). EB1010 discovered using Enterome's Mimicry platform, expected to enter clinical trials in 2023. Partnership also aims to identify and create a pipeline of AllerMimics for food allergies with initial focus on peanut allergens.
• Takeda Pharmaceutical CompanycoreStrategic or Co-development PartnerGlobal licensing, co-development and co-commercialization partnership for sibofimloc (TAK-018), a first-in-class gut-restricted FimH-blocker for Crohn's disease. Sibofimloc is advancing through Phase 2a clinical trial with data readout expected H1 2023. Enterome's unique technologies validated the FimH target as underlying cause of Crohn's disease.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Broad incumbents

• BioNTech: Large mRNA-based immunotherapy company with multiple oncology vaccine programs including individualized neoantigen therapies and off-the-shelf FixVac candidates. Competes in cancer immunotherapy space with significantly greater resources and pipeline breadth.
• Moderna: Major mRNA therapeutics company with oncology vaccine pipeline (mRNA-4157/V940) in melanoma and other solid tumors. Competes with Enterome in next-generation cancer immunotherapy and has significantly greater financial and clinical development resources.

Emerging players

• Hookipa Pharma: Clinical-stage immuno-oncology company developing arenavirus-based immunotherapies for cancer and infectious diseases. Comparable in clinical stage, oncology immunotherapy focus, and emerging biotech profile with platform-based approach.
• Adaptimmune Therapeutics: Clinical-stage cell therapy company developing SPEAR T-cell therapies for solid tumors. Comparable in clinical-stage oncology immunotherapy development, though focused on cell therapy rather than peptide vaccines.
• MaaT Pharma: Clinical-stage microbiome-based therapeutics company developing gut microbiota therapies for cancer and inflammatory diseases. Competes in the microbiome-derived therapeutics space with direct investor overlap (Seventure Partners' Isabelle de Cremoux serves on both boards).
• Vaxcyte: Clinical-stage vaccine company developing novel conjugate vaccines and peptide immunotherapies. Board member connection (Peter Hirth is on Vaxcyte's board) and similar biotech-stage development profile in vaccine/immunotherapy space.

Direct peers

• ISA Pharmaceuticals: Clinical-stage immuno-oncology company developing synthetic long peptide (SLP) vaccines targeting HPV-related cancers and other solid tumors. Direct competitor in therapeutic cancer peptide vaccines, with overlapping management connections (Enterome's CMO Jan Fagerberg was previously ISA's CMO).
• Nouscom: Clinical-stage biotech developing off-the-shelf viral vector-based neoantigen cancer vaccines. Competes in the cancer immunotherapy vaccine space targeting solid tumors with similar strategic positioning to Enterome's OncoMimics platform.
• IO Biotech: Clinical-stage immuno-oncology company developing off-the-shelf therapeutic cancer vaccines based on immune-modulating technologies. Direct competitor in the cancer peptide vaccine space with similar therapeutic approach and target indications.
• Immatics: Clinical-stage biopharmaceutical company developing TCR-based immunotherapies and cancer vaccines (IMA203, IMA401) for solid tumors. Competes in next-generation cancer immunotherapy with multi-platform approach and Phase 1/2 assets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/enterome
• Xx.com/EnteromeSA

Revenue estimate

Valuation estimate

Number of profiles

Profiles13 records

Funding overview

Funding rounds10 records

Investors15 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ENTEROME